Telix Pharmaceuticals Q4 Revenue Climbs
(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) on Tuesday reported a rise in revenue for the fourth quarter, helped by increased revenue from the Precision Medicine segment and RLS third-party.
For the three-month period to December 31, 2025, the company posted revenue of $208 million, higher than $142 million in the same period last year.
Revenue from the Precision Medicine segment moved up to $161 million from $139 million a year ago. RLS third-party revenue stood at $45 million, compared with $00.00 million last year.
TLX was down by 1.03% at $7.68 in the pre-market trade on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.